Lorlatinib, a third-generation, highly-effective, and selective ALK/ROS1 TKI against a broad range of ALK kinase domain-resistant mutations, and known for its significant central nervous system penetration,307 was granted accelerated FDA approval in 2018 for NSCLC patients with ALK rearrangements who have progressed on first-line alectinib, brigatinib, or crizotinib therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.